Suppr超能文献

糖尿病肾病诊断和管理中管状生物标志物的评价和讨论。

Review and discussion of tubular biomarkers in the diagnosis and management of diabetic nephropathy.

机构信息

Dipartimento di Medicina Interna, Sezione di Nefrologia, Università di Pisa, Pisa, Italy.

出版信息

Endocrine. 2013 Jun;43(3):494-503. doi: 10.1007/s12020-012-9820-y. Epub 2012 Oct 20.

Abstract

The prevalence of diabetic nephropathy has tremendously increased with the relentless rise in the incidence of diabetes over the last couple decades. Diabetic nephropathy is a leading cause of morbidity and mortality, and it invariably leads to an end-stage renal disease (ESRD). In an effort to delay the onset of ESRD systematic screening and appropriate management are needed to evaluate the progression of renal damage in diabetic nephropathy. The reliability of current tests in predicting the onset, progression and response to various regimens for diabetic nephropathy is still under debate; and it has engendered a search for more sensitive and specific urinary biomarkers, especially those reflective of tubular dysfunctions. It is well-known that there is a good correlation between the degree of damage to the tubulo-interstitial compartment and the deterioration of renal functions. In view of this, the utility of urinary biomarkers, reflective of tubular injury, reported in the literature is discussed in this brief review.

摘要

过去几十年中,糖尿病的发病率不断上升,导致糖尿病肾病的患病率也大幅增加。糖尿病肾病是发病率和死亡率的主要原因,并且它总是会导致终末期肾病(ESRD)。为了延缓 ESRD 的发生,需要进行系统的筛查和适当的管理,以评估糖尿病肾病中肾脏损害的进展情况。目前的检测方法在预测糖尿病肾病的发生、进展和对各种治疗方案的反应方面的可靠性仍存在争议;这促使人们寻找更敏感和特异的尿生物标志物,特别是那些反映肾小管功能障碍的标志物。众所周知,肾小管-间质腔的损伤程度与肾功能的恶化之间存在很好的相关性。有鉴于此,本文简要综述了文献中报道的反映肾小管损伤的尿生物标志物的应用。

相似文献

1
Review and discussion of tubular biomarkers in the diagnosis and management of diabetic nephropathy.
Endocrine. 2013 Jun;43(3):494-503. doi: 10.1007/s12020-012-9820-y. Epub 2012 Oct 20.
2
Tubular biomarkers to assess progression of diabetic nephropathy.
Kidney Int. 2011 May;79(10):1042-4. doi: 10.1038/ki.2011.9.
4
Clinical implication of urinary tubular markers in the early stage of nephropathy with type 2 diabetic patients.
Diabetes Res Clin Pract. 2012 Aug;97(2):251-7. doi: 10.1016/j.diabres.2012.02.019. Epub 2012 Mar 21.
6
Renal tubular markers in pregnant women with and without gestational diabetes mellitus: a pilot study.
Endocrine. 2015 Jun;49(2):563-5. doi: 10.1007/s12020-014-0511-8. Epub 2014 Dec 25.
7
Changes of the tubular markers in type 2 diabetes mellitus with glomerular hyperfiltration.
Diabetes Res Clin Pract. 2012 Jan;95(1):105-9. doi: 10.1016/j.diabres.2011.09.031. Epub 2011 Oct 20.
8
[Evaluation of tubulointerstitial injury by new biomarkers].
Nihon Jinzo Gakkai Shi. 2011;53(4):596-9.
9
[Early biomarker for AKI].
Nihon Jinzo Gakkai Shi. 2010;52(5):566-71.
10
Urinary tubular biomarkers in short-term type 2 diabetes mellitus patients: a cross-sectional study.
Endocrine. 2012 Feb;41(1):82-8. doi: 10.1007/s12020-011-9509-7. Epub 2011 Jul 21.

引用本文的文献

2
3
Current update on theranostic roles of cyclophilin A in kidney diseases.
Theranostics. 2022 May 13;12(9):4067-4080. doi: 10.7150/thno.72948. eCollection 2022.
4
Analysis of the Clinical Effects of the Combination of Mycophenolate Mofetil with Either Tacrolimus or Cyclophosphamide.
Clinics (Sao Paulo). 2020 Nov 11;75:e1820. doi: 10.6061/clinics/2020/e1820. eCollection 2020.
5
Cyclophilin A (CyPA) as a Novel Biomarker for Early Detection of Diabetic Nephropathy in an Animal Model.
Diabetes Metab Syndr Obes. 2020 Oct 20;13:3807-3819. doi: 10.2147/DMSO.S260293. eCollection 2020.
6
Impaired Glomerular Filtration Rate in Type 2 Diabetes Mellitus Subjects: A Nationwide Cross-Sectional Study in Thailand.
J Diabetes Res. 2020 Aug 12;2020:6353949. doi: 10.1155/2020/6353949. eCollection 2020.
7
Gene expression-based analysis identified NTNG1 and HGF as biomarkers for diabetic kidney disease.
Medicine (Baltimore). 2020 Jan;99(1):e18596. doi: 10.1097/MD.0000000000018596.
8
The effect of A1 adenosine receptor in diabetic megalin loss with caspase-1/IL18 signaling.
Diabetes Metab Syndr Obes. 2019 Aug 28;12:1583-1596. doi: 10.2147/DMSO.S215531. eCollection 2019.
9
Zinc alpha 2 glycoprotein as an early biomarker of diabetic nephropathy in patients with type 2 diabetes mellitus.
J Bras Nefrol. 2019 Oct-Dec;41(4):509-517. doi: 10.1590/2175-8239-JBN-2018-0200.

本文引用的文献

1
The emerging concept of chronic kidney disease without clinical proteinuria in diabetic patients.
Diabetes Metab. 2012 Oct;38(4):291-7. doi: 10.1016/j.diabet.2012.04.001. Epub 2012 May 22.
3
Cytokines in diabetic nephropathy.
Adv Clin Chem. 2012;56:55-74. doi: 10.1016/b978-0-12-394317-0.00014-5.
4
Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney.
Annu Rev Physiol. 2012;74:351-75. doi: 10.1146/annurev-physiol-020911-153333.
5
Advanced glycation end products-mediated hypertrophy is negatively regulated by tetrahydrobiopterin in renal tubular cells.
Mol Cell Endocrinol. 2012 May 15;355(1):71-7. doi: 10.1016/j.mce.2012.01.018. Epub 2012 Feb 2.
6
Chemotactic cytokine receptor 5 gene polymorphism: relevance to microvascular complications in type 2 diabetes.
Cytokine. 2012 May;58(2):213-7. doi: 10.1016/j.cyto.2012.01.007. Epub 2012 Feb 9.
8
Circulating TNF receptors 1 and 2 predict ESRD in type 2 diabetes.
J Am Soc Nephrol. 2012 Mar;23(3):507-15. doi: 10.1681/ASN.2011060627. Epub 2012 Jan 19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验